A new international consensus statement proposes updated diagnostic criteria for acute severe ulcerative colitis (ASUC), replacing reliance on the 1955 Truelove and Witts criteria with a framework that better reflects modern treatment, particularly patients already receiving outpatient corticosteroids or advanced therapies. The consensus was developed by a Delphi panel of gastroenterologists from Europe, North America and the Asia-Pacific region and was published in Clinical Gastroenterology and Hepatology. For patients already receiving outpatient treatment, the proposed definition requires two of three major criteria plus at least two minor criteria. Major criteria include CRP ≥2× the upper limit of normal, ≥6 bowel…
Author: Abhay Panchal
A new analysis from healthcare education company Covista projects that the U.S. clinician shortage could nearly double by 2040, adding pressure to an already strained healthcare workforce. Healthcare Dive reports that more than 108 million people currently live in primary care shortage areas, with burnout and an aging workforce contributing to the problem. Pasted text The analysis estimates that several interventions could reduce the projected gap. Expanding medical education capacity could address roughly a quarter of the shortage, while improving retention and reducing burnout could mitigate about 25%. Covista also estimates that AI tools that automate administrative work could address…
In a Medscape interview, Colleen Kelly, MD, a gastroenterologist at Brigham and Women’s Hospital and Harvard Medical School faculty member, discusses the evolving role of fecal microbiota transplantation (FMT), research beyond C. difficile, obesity in IBD, and the importance of preserving physician-patient connection. Kelly notes that FDA-approved FMT products have largely replaced conventional FMT for preventing recurrent C. difficile infection, but acute severe or fulminant CDI remains a therapeutic gap, particularly for critically ill patients who may require multiple doses. Researchers are exploring open-label and registry data because placebo-controlled trials in this population raise ethical challenges. She also discusses an…
The U.S. Multi-Society Task Force on Colorectal Cancer has published a new review and consensus statement on serrated polyposis syndrome (SPS), emphasizing that the condition is frequently underrecognized despite being associated with increased colorectal cancer risk. The task force recommends using the 2019 WHO criteria for diagnosis and systematically documenting the number, size and location of serrated polyps when multiple lesions are identified. Pasted text For patients with SPS, the recommendations favor endoscopic management over surgery when there is no concurrent CRC. Colonoscopy should be performed by endoscopists with a documented sessile serrated lesion detection rate of at least 6%,…
Tiny Health has raised $33 million in an oversubscribed Series B, led by B Capital, bringing its total funding to $46 million. The company plans to use the funding to expand clinical research, practitioner education and its Powered by Tiny platform for healthcare and consumer-health partners. The company offers gut microbiome testing for infants, children and adults, as well as vaginal microbiome testing, using shotgun metagenomic sequencing to characterize microorganisms in patient samples. It is also developing TinyAI, which is designed to provide guidance based on individual microbiome test results and the company’s underlying dataset. Alongside the funding, Tiny Health…
Abbott has launched SimpleScreen CRC, an FDA-approved blood-based colorectal cancer screening test developed and manufactured by Freenome. The test is intended for average-risk adults age 45 and older, particularly those who decline or do not complete preferred stool-based or visual screening options. In the PREEMPT CRC study of more than 48,000 asymptomatic adults, SimpleScreen CRC demonstrated 81.1% sensitivity for colorectal cancer, including 63.5% for Stage I disease, 13.7% sensitivity for advanced precancerous lesions, and 90.4% specificity for advanced colorectal neoplasia. The test uses circulating cell-free DNA (cfDNA) from a blood sample. Abbott says SimpleScreen CRC is covered by Medicare, with…
Jiro Health has announced a content agreement with the American College of Gastroenterology (ACG) to bring ACG guidelines and journal content into its clinician platform. Jiro says its platform will use real-world practice context—including the patients a gastroenterologist treats, procedures performed and clinical questions asked—to surface the ACG evidence most relevant to each clinician. Through Jiro’s Consult feature, ACG guidance can appear within cited responses alongside the relevant guideline recommendation and practice-specific context. For example, when a gastroenterologist asks about surveillance after removal of a small adenoma, the platform can surface the applicable ACG recommendation and compare surveillance intervals seen…
CapsoVision has received FDA clearance for AI Highlights, an AI-assisted reading tool for its CapsoCam Plus wireless capsule endoscopy system. The tool is designed for adult and pediatric patients over age 2 undergoing small-bowel capsule endoscopy for suspected bleeding. AI Highlights analyzes capsule video frames and identifies and highlights images containing suspected abnormal lesions, allowing physicians to prioritize those images during review. The technology is integrated into CapsoVision’s CapsoView image-review software and CapsoCloud workflow, which can support remote physician review and case management. The company says the tool is intended to help reduce the time required to review capsule endoscopy…
WovenX Health has announced a GI procedure partner network spanning all 50 states and Washington, D.C. as part of a national colorectal cancer screening navigation program. Beginning next month, the program will help patients with positive stool-based colorectal cancer screening results connect with participating GI practices for follow-up colonoscopy. The initiative builds on WovenX’s Fast Track pathway. Patients who opt in can complete a pre-procedural intake and select a participating GI provider, with the intake information shared securely with the receiving practice to support scheduling and procedural readiness. The need is substantial: WovenX cites a 2023 JAMA Network Open study…
In the latest edition of The Scope Forward Show – AI Edition, I’m joined by my co-hosts, Matt Schwartz, Founder & CEO of Virgo and Dr. Neil Parikh, Chief Innovation Officer, Connecticut GI and Chair of Innovation, GI Alliance. Together we discuss the widening gap between AI capabilities and clinical adoption in gastroenterology – from precise polyp segmentation and personalized surveillance to agents handling referrals and patient calls. We explore patient data security, the risks of self-improving AI, and why clinicians must participate while reflecting on what they want this technology to solve. More importantly, we discuss the recent risks of AI that…
